NHS Milton Keynes CCG Priorities Policy

Policy Statement: General Policy on Funding Medicines

Date of Issue: May 2011 as updated January 2016

NHS Milton Keynes CCG notes that there are local and national mechanisms in place to provide advice on the use of medicines. These include:

Medicines and Healthcare products Regulatory Authority (MHRA) determines the approved indications for which a medicine may be licensed for use.

The National Institute for Health and Clinical Excellence (NICE) determines which medicines are clinically and cost effective for use within the NHS.

The Milton Keynes Prescribing Advisory Group determines which medicines are approved for use on the local formulary.

Taking into account these sources of guidance, NHS Milton Keynes CCG recommends that the following should be considered as **Low Priority**

---

PBR excluded medicines for unlicensed uses

PBR medicines for indications not covered by NICE Guidance

Any medicine not listed in the Joint Trusts Formulary

Any prescribing of PBR excluded drugs for unlicensed uses or uses not covered by NICE guidance, or of any non-formulary medicine, which does not have approval from NHS Milton Keynes’s treatment decision panel will not be paid for.

---

**Notes:**

1. *Exceptional circumstances may be considered where there is evidence of significant health impairment and there is also evidence of the medicine improving health status.*

2. *Application should be made using the standard IFR submission form.*